- Home
- DSM vs DRUG Comparison
DSM vs DRUG Comparison
Compare DSM & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- DRUG
- Stock Information
- Founded
- DSM 1989
- DRUG 2019
- Country
- DSM United States
- DRUG United States
- Employees
- DSM N/A
- DRUG N/A
- Industry
- DSM Investment Managers
- DRUG Pharmaceuticals and Biotechnology
- Sector
- DSM Finance
- DRUG Health Care
- Exchange
- DSM Nasdaq
- DRUG Nasdaq
- Market Cap
- DSM 301.0M
- DRUG 260.6M
- IPO Year
- DSM N/A
- DRUG N/A
- Fundamental
- Price
- DSM $5.86
- DRUG $36.78
- Analyst Decision
- DSM
- DRUG Strong Buy
- Analyst Count
- DSM 0
- DRUG 3
- Target Price
- DSM N/A
- DRUG $80.00
- AVG Volume (30 Days)
- DSM 161.7K
- DRUG 79.3K
- Earning Date
- DSM 01-01-0001
- DRUG 12-31-2024
- Dividend Yield
- DSM 3.97%
- DRUG N/A
- EPS Growth
- DSM N/A
- DRUG N/A
- EPS
- DSM N/A
- DRUG N/A
- Revenue
- DSM N/A
- DRUG N/A
- Revenue This Year
- DSM N/A
- DRUG N/A
- Revenue Next Year
- DSM N/A
- DRUG N/A
- P/E Ratio
- DSM N/A
- DRUG N/A
- Revenue Growth
- DSM N/A
- DRUG N/A
- 52 Week Low
- DSM $4.69
- DRUG $0.93
- 52 Week High
- DSM $6.05
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- DSM 47.62
- DRUG 46.15
- Support Level
- DSM $5.72
- DRUG $35.02
- Resistance Level
- DSM $5.89
- DRUG $38.00
- Average True Range (ATR)
- DSM 0.06
- DRUG 3.09
- MACD
- DSM 0.01
- DRUG -0.37
- Stochastic Oscillator
- DSM 75.00
- DRUG 30.44
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.